METABOLIC DISORDERS
Osteoporosis: Zoledronic acid increases bone mineral density and reduces fracture rate
Asian Pac J Trop Med. 2012 Sep;5(9):743-8. doi: 10.1016/S1995-7645(12)60118-7This meta-analysis included 9 studies comparing zoledronic acid and a placebo in patients with osteoporosis. Results from the analysis indicated that zoledronic acid was effective in increasing bone mineral density and reducing fracture rate. The zoledronic acid group also demonstrated a significantly lower rate of serious adverse events than the control group. According to subgroup analyses, older patients (over 50 years) and those who received the intervention longer (more than 12 months) benefited most from zoledronic acid.
Unlock the full ACE Report
You have access to {0} free articles per month.Click below to unlock and view this {1}
Unlock NowCritical appraisals of the latest, high-impact randomized controlled trials and systematic reviews in orthopaedics
Access to OrthoEvidence podcast content, including collaborations with the Journal of Bone and Joint Surgery, interviews with internationally recognized surgeons, and roundtable discussions on orthopaedic news and topics
Subscription to The Pulse, a twice-weekly evidence-based newsletter designed to help you make better clinical decisions
Exclusive access to original content articles, including in-house systematic reviews, and articles on health research methods and hot orthopaedic topics
Or upgrade today and gain access to all OrthoEvidence content for just $1.99 per week.
Already have an account? Log in
Subscribe to "The Pulse"
Evidence-Based Orthopaedics direct to your inbox.
{0} of {1} free articles
Become an OrthoEvidence Premium Member. Expand your perspective with high-quality evidence.
Upgrade Now
